still comfort acceler
growth in-lin remain confid acceler
backhalf guidanc creat anoth larg
momentum hurdl comfort
midpoint perform set tone
growth
in-lin organ growth reset mesh paclitaxel neuromod
unexpectedli weigh growth boston deliv organ growth
line mse admittedli expect acut recoveri
top half organ growth rang convinc signal
fundament chang around thesi acceler growth
modest like reflect slower recoveri boston
miss mse us neuromod urolog driven
mesh residu steril impact combin neuromod mesh
account bp quarter delta report
expect growth area strength includ cardiolog
pt momentum acceler driven mid-teen complex pci growth
lotu launch ex us pi growth endoscopi pt momentum
acceler emerg market deliv anoth quarter
y/i growth drive bp growth total boston ep line
mse sg bp higher expect reflect invest
product launch off-set one-tim tax benefit pleas see exhibit
get backhalf guidanc organ growth impli
bp momentum acceler midpoint bp
acceler alway year acceler
comfort boston deliv bp acceler need
backhalf deliv better organ growth year bridg
leav us comfort midpoint impli bp
acceler driver includ sell day benefit split
sentinel rezum turn organ on-going lotu roll-out exhibit
full bridg
estim impli bp momentum deceler
deliv midpoint guidanc feel achiev given partial
sell day benefit exalt cryo single-shot balloon launch sentinel
augmenix turn organ acceler lotu growth contribut
increment mn sale bp creat path top
end organ growth rang see exhibit model
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
midpoint guidanc see path top end rang
see momentum improv balanc versu manag
upsid estim rang would clearli de-risk improv
sentiment
bp bp driven vertiflex post-clos
augmenix impli modest outlook rezum recal
augmenix guidanc rais analyst day see
line model chang post cfo meet see also
highlight modest outlook rezum post cfo meet
reimburs take longer origin anticip
 activ acceler temper
vertiflex milliped expect close btg mid-august
model current includ bp contribut
vertiflex btg close around august next key catalyst
expect updat guidanc post-clos see btg math
expect one deal expect boston remain activ
cours lrp deploy deal annual
investor question boston flurri began last year
analysi suggest last deal drive bp growth
said previous math boston growth
bp key differ maker boston premium multipl
lotu sale mse reflect boston
control roll-out manag commentari support posit
feedback tvt see lotu share expect rel
model assumpt remain comfort steeper growth
curv lotu roll-out acceler
eluvia deliv sale line us trend stabl
prior commentari pacitaxel japan sale strong expect
less sanguin fda review boston clear see
differenti place eluvia rel dcb assum chang
sale impli bp benefit corpor growth
vs expect sale
market still clearli pressur outlook
earn firm boston q/q us vs abbott
see model q/q ww nevro still look
reason see preview albeit conserv
base top tier durabl organ growth boston deliv high
singl digit growth better rel larg cap devic peer growth
continu room margin expans boston deliv bp
annual path oper margin drive mid-
teen ep growth sustain beyond vs doubl digit earn growth
peer flexibl balanc sheet capit previous relat liabil
mesh/tax deploy toward sharehold return
deploy toward versu
avail pt base ep valuat
methodolog base premium larg cap peer base sustain
high singl digit organ growth profil multipl line high
growth peer abbott edward
peer top bottom line growth drive posit risk-reward
peer top bottom line growth drive posit risk-reward
price target base multipl
base case ep assum trade larg cap peer
justifi superior emerg growth margin expans
opportun leverag profil line high growth
peer ew
bull case ep
bull case ep
fire cylind organ growth acceler doubl digiti
pipelin program outperform sale inflect faster expect high
increment profit new growth driver better leverag recent
 acceler margin expans drive high teen greater ep growth
base ep
base ep
sustain execut support acceler high singl digit large-cap growth
stori recent build pipelin program drive sale compound-annual-growth-rate
oper margin remain track bp annual
improv next sever year drive mid-teen ep growth
base case reflect multipl ep estim larg cap
devic given boston attract growth margin expans leverag
profil line high growth peer like ew
bear ep
bear ep
pressur multipl front acquisit prove less accret organ growth
key pipelin product fail come market tavr fail gain traction
stent price share pressur increas weigh organ
matur pipelin augment
drive sustain hsd organ growth
profil bp annual margin
expans drive mid teen ep growth
support premium valuat peer
revenu growth better
sustain boston shift
faster end market share gain
continu wamgr shift today
margin expans driven
integr oper effici balanc
sheet flexibl improv
boston move past mesh ir litig
pipelin focus expand
higher growth end market wamgr move
long term margin expans target
beyond suggest plenti room
continu margin expans
balanc sheet deploy seen
rapid pace
launch pi wavewrit roll-out
neuromod on-going sens
balloon cathet launch ep
integr recent on-going
risk achiev price
increas competit core de
market competit product
failur execut plan pipelin
program integr
million except ep
million
million
million
sale
sale
sale
sale
good sold
plant properti equip net
dollar million except per share data
sale busi
depreci amort
net chang work capit
oper
payment acquisit
proce busi divestitur
payment invest acquisit certain tech
proce invest collect note receiv
invest
payment conting consider
chang long-term debt
chang short-term debt
payment acquisit treasuri stock
use net share settl employe equiti award
proce issuanc share common stock
financ
effect foreign exchang rate cash
begin period
end period
sale busi
depreci amort
net chang work capit
oper
payment acquisit
proce busi divestitur
payment invest acquisit certain tech
proce invest collect note receiv
invest
payment conting consider
chang long-term debt
chang short-term debt
payment acquisit treasuri stock
use net share settl employe equiti award
proce issuanc share common stock
financ
effect foreign exchang rate cash
begin period
end period
